• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Pro-life organization calls on HHS and FDA to suspend abortion pill approval, tighten safety rules

by January 22, 2026
written by January 22, 2026

Live Action, a pro-life organization, is demanding that the Trump administration take action on the distribution of and reporting on mifepristone, often colloquially called ‘the abortion pill.’ 

The group is holding a press conference on Capitol Hill on Thursday to discuss concerns surrounding the abortion drug, as well as a new investigative video from Live Action that the group says documents ‘the dangerous real-world distribution of this drug by Planned Parenthood and affiliated providers.’ The group alleges ‘reckless distribution’ practices and argues the adverse effects of the drug are not being documented properly, if at all.

In a letter to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, Live Action said it aims to show ‘clear evidence of regulatory noncompliance and patient harm’ and to issue a call for immediate action from HHS and the FDA.

The letter urges HHS and the FDA to suspend the approval of mifepristone, prohibit the distribution of abortion pills through mail-order services and telehealth, reinstate comprehensive adverse-event reporting requirements, and release a full public accounting of the scientific and clinical evidence used to expand access to the drug.

‘For more than two decades, mifepristone has remained on the market under an approval process that was politically accelerated, shielded from transparency, and repeatedly expanded without regard for patient safety, adverse event reporting, or statutory compliance,’ the letter, signed by Lila Rose, Live Action founder and president, reads.

The FDA currently allows mifepristone to be prescribed via telehealth appointments and distributed by mail under its risk evaluation and mitigation strategy (REMS) program. The FDA advises against buying mifepristone online outside its REMS program, warning that those who do ‘would be bypassing important safeguards specifically designed to protect their health.’

The letter also references an April 2025 report issued by the Ethics & Public Policy Center (EPPC). The report claims that nearly 11% of women experience adverse side effects within 45 days of taking mifepristone, including sepsis, infection and hemorrhaging.

‘The real-world rate of serious adverse events following mifepristone abortions is at least 22 times as high as the summary figure of ‘less than 0.5 percent’ in clinical trials reported on the drug label,’ the EPPC report summary states.

Live Action also put out a video purportedly showing real calls with 27 Planned Parenthood locations across the U.S. In the video, a woman speaks with various Planned Parenthood locations about obtaining the abortion pill. The video appears to feature Planned Parenthood facilities in Alaska, Colorado, Kansas, Oregon, Minnesota, New Mexico and New York, with some states appearing multiple times.

The first section shows the woman asking whether the clinics need to see ultrasounds before prescribing the pill in order to assess the gestational age of the fetus. Many of those answering the phones at the Planned Parenthood locations said women could obtain the pill without an ultrasound through a telehealth appointment.

In the second section, the woman who called was told that Planned Parenthood would not test for Rhesus (Rh) incompatibility. Rh is a protein that some people carry in their blood, and it can cause issues in future pregnancies. 

A form from Planned Parenthood of Greater New York dated March 2020 states that, ‘There is a chance you might make Rh antibodies and have problems with future pregnancies. Research has not proved this.’

Live Action’s video also purportedly showed that those who answered the phone at multiple Planned Parenthood locations assured the women that they did not need to give their medical history or attend an in-person follow-up.

It was unclear if the individuals who spoke with the woman had medical training. One suggested that the woman speak to a medical professional to get more accurate information on specific questions.

Those who answered the phone for clinics in multiple states also said the caller would be able to have the pills sent to another person’s house. When asked whether the pills needed to be taken right away, most said they did not, with many assuring the woman calling that she could change her mind or wait to make a decision. However, the person on the phone at one clinic said that the woman had until 12 weeks to take the pill and advised that it would not be effective after that time.

Live Action released its letter and accompanying video ahead of the annual March for Life, which is scheduled for Jan. 23. Vice President JD Vance, who recently announced that he and his wife, Usha, are expecting their fourth child, is slated to speak at the march, as he did in 2025. Other speakers include House Speaker Mike Johnson, R-La., and Rep. Chris Smith, R-N.J.

In a statement to Fox News Digital, Planned Parenthood said its health centers that offer medication abortion ‘follow all applicable laws and regulations and always ensure care provided reflects the latest credible research and upholds the highest standard of patient care.’ 

‘In accordance with Planned Parenthood Federation of America’s medical standards and guidelines — which are developed and updated with medical experts across the field of sexual and reproductive health care using rigorous scientific evidence — providers at Planned Parenthood health centers explain the associated risks and benefits to patients seeking medication abortion, just as they do with every health care service provided,’ Danika Severino, Planned Parenthood vice president of care and access, said in a statement.

‘Mifepristone is safe, legal, and has been used by more than 7.5 million people for abortion and miscarriage care since its approval by the U.S. Food and Drug Administration (FDA) 25 years ago,’ Severino added. ‘Despite 25 years of data and more than 100 peer-reviewed studies proving mifepristone is extremely safe and effective, anti-abortion activists continue to spread disinformation to advance their harmful political agenda.’  

Fox News Digital also reached out to HHS and the FDA for comment.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
SCOOP: White House backs impeaching ‘rogue’ judges accused of partisan rulings
next post
State Dept moves to expand Mexico City Policy, targeting abortion, DEI and gender ideology in foreign aid

related articles

Sanders caught on camera snapping at reporter over...

May 21, 2026

WATCH: Wesley Hunt flips script on Dems’ ‘Jim...

May 21, 2026

Trump fires warning shot at SCOTUS as major...

May 21, 2026

Senate GOP erupts over Trump DOJ ‘anti-weaponization’ fund,...

May 21, 2026

Former Detroit mayor blows governor’s race wide open...

May 21, 2026

Microbiologist one step closer to winning late Democrat’s...

May 20, 2026

Omar breaks silence on alleged fraud connections in...

May 20, 2026

Trump’s endorsement put to the test in Alabama...

May 20, 2026

Trump jolts immigration hawks with surprising defense of...

May 20, 2026

Trump-backed nominees dominate primary contests as president tightens...

May 20, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Trump attorney Alina Habba not considering press secretary role

    November 14, 2024
  • Republicans, Dems break through resistance, move forward with Trump-backed funding package

    January 30, 2026
  • Morgan Stanley cuts global equities, boosts cash and US Treasuries

    March 30, 2026
  • DAVID MARCUS: Why Teamsters members think Trump, not Harris, is the real friend of the working man

    September 18, 2024
  • Optimus, Elon Musk’s Tesla Robot to Be Released This Year

    July 10, 2024

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    CoreWeave eyes $1.5B bond raise to ease debt load following lacklustre IPO: report

    May 9, 2025
  • 5

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024

Categories

  • Economy (829)
  • Editor's Pick (8,526)
  • Investing (2,723)
  • Stock (1,028)

Latest Posts

  • Gold and Silver: Gold is bullish again this morning

    August 23, 2024
  • FS KKR stock slides as Moody’s downgrade flags rising credit stress

    March 24, 2026
  • Trump’s ‘they/them’ ads combined culture war, economic worries to make effective pitch: expert

    November 8, 2024

Recent Posts

  • Tesla stock struggles as delivery fears and Musk bets test investor faith

    March 27, 2026
  • UniCredit posts record €3.2B Q1 profit, its 21st straight winning quarter

    May 5, 2026
  • The dollar index begins to recover from morning’s support

    August 28, 2024

Editor’s Pick

  • Biden is on the way out and Trump is taking the wheel. Welcome back, America

    January 17, 2025
  • India’s Meesho surges 60% after listing as investor demand for tech IPO surge

    December 10, 2025
  • DAVID MARCUS: Camping out with Democrat dimwits

    February 6, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock